Sydney M Crago

David S. Boyer, MD will present data from the sozinibercept Phase 2b wet AMD trial.

Ramiro Ribeiro, MD, PhD, shares insights from the ongoing research tyrosine kinase inhibitors for AMD and DME.

In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA lesion growth of 66% at 3 months.

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration.

The objective of this trial was to evaluate safety and tolerability and identify dose level for further evaluation.

OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

This phase 2b study (ASPIRE) is currently underway.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas.

Several pharmaceutical companies have announced new appointments of executives and board members as they prepare for growth in 2025.

Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding that you may have missed.

The collaboration between KIST and Huons BioPharma will span 14 months.

Most recently, Jacques served as Vice President of Healthcare Strategy, Partnerships & M&A at Microsoft.

The potential gene therapy candidate is being evaluated for geographic atrophy.

The conference will be held January 13-16, 2025 in San Francisco, CA.

Let’s look back on some of the top stories on Modern Retina from 2024 as we gear up for an incredible 2025.

Did you miss any of our print issues this year? Don’t worry, they are still available online.

Curacle plans to finalize its development strategy, including phase 2b and 3 trials, through a Type C meeting with the US FDA in February of 2025.

The publication is entitled, “Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies.”

In the statement, the board calls attention to a proposal by a committee in the US House of Representatives that would shrink the National Institutes of Health’s (NIH) from 27 institutes into 15 institutes.

Espansione Group is known for photobiomodulation (PBM) technology – the Light Modulation Low-level Light Therapy (LLLT) along with the Intense Pulsed Light (IPL) technology.

Within 4 months of AEYE-DS's deployment, diabetic retinopathy screening adherence increased from 29 percent to 49 percent.

Kaczmarek has a notable background of executive leadership and operational expertise in the gene therapy manufacturing industry.

This interview comes at the Children's Hospital Los Angeles team celebrates its 100th retinal gene therapy procedure.

The aim of this program is to help advance junior clinical research scientists in their professional endeavors to cure retinal degenerative disease.

This study was published online in the journal Aging Cell and reveals how DNA damage compromises the retina’s function and accelerates vision loss.

Roche, Ainnova, and Salud 360 signed this alliance to improve access to vision screening in patients with uncontrolled diabetes.

ACELYRIN will not make any additional internal investment in developing izokibep.

EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in development.

The report is titled, Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast-2034.